Tagged with DCB

Taiwan Biotechnology has long been a strategic priority for Taiwan’s economic development, standing alongside ICT and semiconductors as a key pillar of growth for the island. Driven by a highly educated scientific workforce and competitive development costs, Taiwan is a natural hub for early-phase drug development and initial manufacturing. However, only…

Taiwan Biotechnology in Taiwan is no longer a future aspiration, but an industrial system deliberately built for global relevance. In this conversation, the Chairman and CEO of the Development Centre for Biotechnology explain how policy, data, manufacturing discipline, and clinical capability are being aligned to create a coherent national ecosystem. The…

Taiwan Lawrence Gan, President and CEO of Taiwan’s Development Center for Biotechnology (DCB) explains his vision and strategy to enhance DCB’s R&D expertise by adopting some of the best practices of the corporate world. You became head of Taiwan’s Development Center for Biotechnology after having held prestigious positions in the US…

Array In Taiwan, biotech is finally booming, and more and more of the companies benefitting from this boom are listing on the Gre Tai Securities Market (GTSM), built with small to medium enterprises in mind, and tailored for companies that are part of emerging industries. But are these companies overvalued, and…

Basic Research A leading figure in the Taiwanese pharmaceutical sector, Lee divulges the practicalities behind ECFA, the free trade agreement that was signed between China and Taiwan in 2010 but has not yet come into full force; questions whether a lack of multinational investment has been a major disadvantage for Taiwan; explains…